BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barak N, Beck Y, Albeck JH. A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain. Journal of Clinical Psychopharmacology 2016;36:253-6. [DOI: 10.1097/jcp.0000000000000489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Di Giovanni G, Svob Strac D, Sole M, Unzeta M, Tipton KF, Mück-Šeler D, Bolea I, Della Corte L, Nikolac Perkovic M, Pivac N, Smolders IJ, Stasiak A, Fogel WA, De Deurwaerdère P. Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. Front Neurosci 2016;10:541. [PMID: 27932945 DOI: 10.3389/fnins.2016.00541] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
2 El-Nabarawi MA, Ali AA, Aboud HM, Hassan AH, Godah AH. Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation. Drug Des Devel Ther 2016;10:4031-45. [PMID: 28008227 DOI: 10.2147/DDDT.S120613] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
3 Cheng L, Liu J, Chen Z. The Histaminergic System in Neuropsychiatric Disorders. Biomolecules 2021;11:1345. [PMID: 34572558 DOI: 10.3390/biom11091345] [Reference Citation Analysis]
4 Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017;13:2231-41. [PMID: 28883731 DOI: 10.2147/NDT.S113099] [Cited by in Crossref: 118] [Cited by in F6Publishing: 68] [Article Influence: 23.6] [Reference Citation Analysis]
5 El-Menshawe SF, Ali AA, Halawa AA, Srag El-Din AS. A novel transdermal nanoethosomal gel of betahistine dihydrochloride for weight gain control: in-vitro and in-vivo characterization. Drug Des Devel Ther 2017;11:3377-88. [PMID: 29238164 DOI: 10.2147/DDDT.S144652] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
6 Connor CJ. Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines. Clin Cosmet Investig Dermatol 2017;10:117-32. [PMID: 28458571 DOI: 10.2147/CCID.S111041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]